Integrin-targeting protein and methods of use thereof

A technology of integrin and pharmaceutical composition, which is applied in the field of diseases and conditions related to portal hypertension and fibrosis, and the field of cancer treatment, and can solve problems that hinder the success of the development of therapeutic agents

Active Publication Date: 2018-02-16
GEORGIA STATE UNIV RES FOUND INC +1
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Restrictions on one or more targeting sites and one or more mechanisms of action hamper the successful drug development of these therapeutics

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Integrin-targeting protein and methods of use thereof
  • Integrin-targeting protein and methods of use thereof
  • Integrin-targeting protein and methods of use thereof

Examples

Experimental program
Comparison scheme
Effect test

example

[0174] Experiment with PC-3 xenograft to compare ProAgio-PEG Comparison of the impact and ProAgio-PEG Impact. As with with In contrast, ProAgio-PEG is more effective in inhibiting tumor growth (in Figure 38 to Figure 41 Shown in).

[0175] In addition, ProAgio-PEG treatment reduces blood vessels more than with The degree of blood vessel reduction is higher (not shown).

[0176] Tumor angiogenesis is usually affected by the microenvironment surrounding the tumor. Therefore, an orthotopic model using immunocompatible mice was performed. Specifically, Balb / c mice were used for experiments with murine mammary 4T-1 cells. The tumor-bearing mice were treated with the same dosage regimen of ProAgio-PEG or D1-CD2-PEG. Treatment started on the fifth day after tumor inoculation. There was a significant difference in tumor growth between the ProAgio-PEG-treated group and the buffer-treated group (in Figure 42 with Figure 43 Shown in ), indicating that ProAgio is effective in inhi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A non-toxic anti-angiogenesis protein that inhibits tumor growth and exhibits in vitro activity in induction of angiogenic endothelial cell apoptosis without targeting VEGF / VEGFR or any other RTK pathways is described. The protein targets integrins [Alpha]<v>[beta]<3>, at a groove in the [beta]A domain of [beta]<3> formed by [Alpha]2 helix, B-C loop, and [Alpha]2-[Alpha]3 loop.

Description

[0001] Related application [0002] This application claims the benefit of U.S. Provisional Patent Application 62 / 129,499 filed on March 6, 2015, which is incorporated herein by reference in its entirety. [0003] Government rights [0004] The present invention was made under CA175122 granted by the National Institutes of Health with government support. The government has certain rights in this invention. Technical field [0005] This application relates to compounds or proteins that may be suitable for the treatment of medical conditions associated with fibrosis. The present disclosure generally relates to specific binding to integrin a v β 3 Of peptides. The present disclosure further relates to methods of using polypeptides for reducing angiogenesis, cell proliferation, and fibrosis, as well as for treating cancer, portal hypertension, and fibrosis-related diseases and conditions. Background technique [0006] Generally, solid tumors cannot grow beyond 3 to 4 mm in diameter wit...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/705C12N15/12A61K38/17
CPCC07K14/70546A61K38/1774A61K38/00A61P1/16A61P1/18A61P15/14A61P35/00A61P35/02A61P43/00A61K47/60C07K14/70557
Inventor 刘知人查卡·拉维依·图拉戈詹妮·杨
Owner GEORGIA STATE UNIV RES FOUND INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap